NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $1.12 +0.03 (+2.75%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.07▼$1.1450-Day Range$0.51▼$1.2552-Week Range$0.45▼$1.60Volume703,805 shsAverage Volume1.73 million shsMarket Capitalization$253.37 millionP/E RatioN/ADividend YieldN/APrice Target$7.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Gossamer Bio alerts: Email Address Gossamer Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside603.1% Upside$7.88 Price TargetShort InterestHealthy4.06% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.76Based on 5 Articles This WeekInsider TradingAcquiring Shares$249,240 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.41) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.45 out of 5 starsMedical Sector120th out of 936 stocksPharmaceutical Preparations Industry43rd out of 436 stocks 3.4 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 4 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.06% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 4.57%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Gossamer Bio is -0.67. Previous Next 2.6 News and Social Media Coverage News SentimentGossamer Bio has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Gossamer Bio this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have bought 19,696.66% more of their company's stock than they have sold. Specifically, they have bought $249,240.00 in company stock and sold $1,259.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.41) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gossamer Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Gossamer Bio Stock (NASDAQ:GOSS)Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More GOSS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOSS Stock News HeadlinesJuly 25 at 7:08 AM | msn.comWhy Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now?July 20, 2024 | americanbankingnews.comGossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! June 13, 2024 | investorplace.comThe Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall StreetMay 21, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Gossamer Bio on Seralutinib’s Promising Clinical Data and Future ProspectsMay 14, 2024 | businesswire.comGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceMay 10, 2024 | businesswire.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity GrowthJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 9, 2024 | bizjournals.comCary headquarters plays crucial role in $160 million dealMay 8, 2024 | msn.comGossamer Bio and Chiesi partner for pulmonary hypertension treatmentMay 7, 2024 | businesswire.comGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | markets.businessinsider.comBuy Rating on Gossamer Bio Supported by Strategic Partnership and Market UnderestimationMay 6, 2024 | finance.yahoo.comUPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung conditionMay 6, 2024 | finance.yahoo.comGossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions WorldwideMay 6, 2024 | reuters.comGossamer Bio and Chiesi Group to collaborate for blood pressure treatmentMay 3, 2024 | businesswire.comGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineMay 2, 2024 | msn.comWhat Ralph Waldo Emerson Knew About MoneySee More Headlines Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$7.88 High Stock Price Target$15.00 Low Stock Price Target$1.25 Potential Upside/Downside+603.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-525.73% Return on Assets-62.70% Debt Debt-to-Equity Ratio7.37 Current Ratio7.13 Quick Ratio7.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book4.00Miscellaneous Outstanding Shares226,220,000Free Float214,908,000Market Cap$253.37 million OptionableOptionable Beta1.93 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Faheem Hasnain (Age 66)Co-Founder, CEO, President & Chairman Comp: $910.26kMr. Bryan Giraudo (Age 49)COO & CFO Comp: $708.09kMr. Robert P. Smith (Age 55)Chief Commercial Officer Comp: $135.79kMr. Christian Waage (Age 57)Executive Vice President of Technical Operations & Administration Comp: $583.16kMr. Jeff BoernekeGeneral Counsel & SecretaryMs. Deanna WeberSenior Vice President of Human ResourcesDr. Richard Aranda M.D. (Age 63)Chief Medical Officer Comp: $625.24kMr. Mario OrlandoSenior Vice President of Commercial New Product PlanningMs. Caryn L. Peterson (Age 65)Executive Vice President of Regulatory Affairs Mr. Matt CravetsSenior Vice President of BiometricsMore ExecutivesKey CompetitorsSinovac BiotechNASDAQ:SVAAlbireo PharmaNASDAQ:ALBOPacira BioSciencesNASDAQ:PCRXAbCellera BiologicsNASDAQ:ABCLImmunomeNASDAQ:IMNMView All CompetitorsInsiders & InstitutionsSequoia Financial Advisors LLCBought 20,000 shares on 7/16/2024Ownership: 0.041%Richard ArandaSold 1,908 sharesTotal: $1,259.28 ($0.66/share)Faheem HasnainBought 372,000 shares on 6/21/2024Total: $249,240.00 ($0.67/share)Jacobs Levy Equity Management Inc.Sold 468,964 shares on 5/16/2024Ownership: 0.722%Price T Rowe Associates Inc. MDSold 804,222 shares on 5/15/2024Ownership: 1.278%View All Insider TransactionsView All Institutional Transactions GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $0.9125 at the beginning of 2024. Since then, GOSS shares have increased by 22.7% and is now trading at $1.12. View the best growth stocks for 2024 here. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's top institutional shareholders include Sequoia Financial Advisors LLC (0.04%). Insiders that own company stock include Faheem Hasnain, Richard Aranda, Bryan Giraudo, Laura Carter and Caryn Peterson. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC) and NVIDIA (NVDA). This page (NASDAQ:GOSS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
